ReST Therapeutics is a Clinical Biotech leveraging its successful Seed Funding to advance our proprietary drug candidate through non-clinical testing and achieve the First in Human clinical study by end of 2023.
ReST develops breakthrough therapies to treat complex CNS disorders, in particular, various forms of Post-Traumatic Stress Disorder (PTSD) and Alzheimer’s Disease (AD). Our first candidate is Fluoro Ethyl Nor-Memantine (FENM), a new molecule selectively targeting NMDA receptors.
Chief Operating Officer and GM France
Life Science Entrepreneur. Former Pharmaceutical BU director of M2I.
Inventor of FENM activity. Experienced manager of strategic alliances and R&D research consortia.
Chief Medical Officer
Physician, anesthesiologist and intensivist. Former ANSM director for SNC products.
Expert in NMDAr structure and function. Specialist in regulatory affairs and clinical trial design.
ReST Therapeutics announces the endorsement by the European Medicine Agency (EMA) to enter the clinical phase and request First in Human (FIH)...
FENM appeared as a potent neuroprotective drug in an AD model, with a superior efficacy compared with Memantine and an absence of direct amnesic effect at higher doses.
ReST Therapeutics announces that Pr. John Krystal has joined its Scientific Advisory Board ReST Therapeutics, clinical-stage biotech company...
On October 11, 2022, the USPTO issued ReST Therapeutics a patent on the use of its drug candidate FENM for the treatment of anxiety and PTSD. ReST...
A new patent for Biotech ReST Therapeutics as part of its search for solutions against Post-Traumatic Syndrome and Alzheimer’s
On May 6, the National Institute of Intellectual Property (INPI) issued ReST Therapeutics and its academic co-owners (University of Montpellier,...
Biological Psychiatry Published: May 09, 2021DOI: https://doi.org/10.1016/j.biopsych.2021.04.024...
International Journal of Neuropsychopharmacology, 2021 Jul 14;24(6):519-531. https://doi.org/10.1093/ijnp/pyab007 Fluoroethylnormemantine, A Novel...